Your browser doesn't support javascript.
loading
Formate overflow drives toxic folate trapping in MTHFD1 inhibited cancer cells.
Green, Alanna C; Marttila, Petra; Kiweler, Nicole; Chalkiadaki, Christina; Wiita, Elisée; Cookson, Victoria; Lesur, Antoine; Eiden, Kim; Bernardin, François; Vallin, Karl S A; Borhade, Sanjay; Long, Maeve; Ghahe, Elahe Kamali; Jiménez-Alonso, Julio J; Jemth, Ann-Sofie; Loseva, Olga; Mortusewicz, Oliver; Meyers, Marianne; Viry, Elodie; Johansson, Annika I; Hodek, Ondrej; Homan, Evert; Bonagas, Nadilly; Ramos, Louise; Sandberg, Lars; Frödin, Morten; Moussay, Etienne; Slipicevic, Ana; Letellier, Elisabeth; Paggetti, Jérôme; Sørensen, Claus Storgaard; Helleday, Thomas; Henriksson, Martin; Meiser, Johannes.
Affiliation
  • Green AC; Weston Park Cancer Centre and Mellanby Centre for Musculoskeletal Research, Department of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield, UK.
  • Marttila P; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
  • Kiweler N; Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.
  • Chalkiadaki C; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
  • Wiita E; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
  • Cookson V; Weston Park Cancer Centre and Mellanby Centre for Musculoskeletal Research, Department of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield, UK.
  • Lesur A; Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.
  • Eiden K; Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.
  • Bernardin F; Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.
  • Vallin KSA; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
  • Borhade S; RISE Research Institutes of Sweden, Södertälje, Sweden.
  • Long M; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
  • Ghahe EK; RedGlead Discover, Lund, Sweden.
  • Jiménez-Alonso JJ; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
  • Jemth AS; Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
  • Loseva O; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
  • Mortusewicz O; Department of Pharmacology, Faculty of Pharmacy, University of Seville, Seville, Spain.
  • Meyers M; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
  • Viry E; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
  • Johansson AI; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
  • Hodek O; Faculty of Science, Technology and Medicine, Department of Life Sciences and Medicine, Molecular Disease Mechanisms Group, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
  • Homan E; Tumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.
  • Bonagas N; Swedish Metabolomics Centre, Department of Plant Physiology, Umeå University, Umeå, Sweden.
  • Ramos L; Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, Umeå, Sweden.
  • Sandberg L; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
  • Frödin M; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
  • Moussay E; Weston Park Cancer Centre and Mellanby Centre for Musculoskeletal Research, Department of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield, UK.
  • Slipicevic A; Drug Discovery and Development Platform, Science for Life Laboratory, Department of Organic Chemistry, Stockholm University, Solna, Sweden.
  • Letellier E; Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
  • Paggetti J; Tumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.
  • Sørensen CS; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
  • Helleday T; One-carbon Therapeutics AB, Stockholm, Sweden.
  • Henriksson M; Faculty of Science, Technology and Medicine, Department of Life Sciences and Medicine, Molecular Disease Mechanisms Group, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
  • Meiser J; Tumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.
Nat Metab ; 5(4): 642-659, 2023 04.
Article de En | MEDLINE | ID: mdl-37012496
ABSTRACT
Cancer cells fuel their increased need for nucleotide supply by upregulating one-carbon (1C) metabolism, including the enzymes methylenetetrahydrofolate dehydrogenase-cyclohydrolase 1 and 2 (MTHFD1 and MTHFD2). TH9619 is a potent inhibitor of dehydrogenase and cyclohydrolase activities in both MTHFD1 and MTHFD2, and selectively kills cancer cells. Here, we reveal that, in cells, TH9619 targets nuclear MTHFD2 but does not inhibit mitochondrial MTHFD2. Hence, overflow of formate from mitochondria continues in the presence of TH9619. TH9619 inhibits the activity of MTHFD1 occurring downstream of mitochondrial formate release, leading to the accumulation of 10-formyl-tetrahydrofolate, which we term a 'folate trap'. This results in thymidylate depletion and death of MTHFD2-expressing cancer cells. This previously uncharacterized folate trapping mechanism is exacerbated by physiological hypoxanthine levels that block the de novo purine synthesis pathway, and additionally prevent 10-formyl-tetrahydrofolate consumption for purine synthesis. The folate trapping mechanism described here for TH9619 differs from other MTHFD1/2 inhibitors and antifolates. Thus, our findings uncover an approach to attack cancer and reveal a regulatory mechanism in 1C metabolism.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Methylenetetrahydrofolate Dehydrogenase (NADP) / Tumeurs Langue: En Journal: Nat Metab Année: 2023 Type de document: Article Pays d'affiliation: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Methylenetetrahydrofolate Dehydrogenase (NADP) / Tumeurs Langue: En Journal: Nat Metab Année: 2023 Type de document: Article Pays d'affiliation: Royaume-Uni